Baird analyst Michael Ha said the weakness in Oscar Health (OSCR) following ts results is a buying opportunity and he expects the shares to trade back to around $18 in the near-term. Baird reiterated its Outperform rating and $28 price target on Oscar Health shares.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSCR: